BIOLASE (BIOLQ)
OTHER OTC:BIOLQ
Top Page
No summary available
Positive Factors
Product Innovation
BIOLASE's focus on innovative dental laser systems positions it well in the medical device sector, offering minimally invasive solutions that can drive long-term adoption and market share growth.
Negative Factors
Financial Challenges
Ongoing financial challenges, including persistent losses and high leverage, threaten BIOLASE's financial stability and ability to invest in growth opportunities.
Read all positive and negative factors
Positive Factors
Negative Factors
Product Innovation
BIOLASE's focus on innovative dental laser systems positions it well in the medical device sector, offering minimally invasive solutions that can drive long-term adoption and market share growth.
Read all positive factors
BIOLASE (BIOLQ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$37.00
Dividend YieldN/A
Average Volume (3M)69.31K
Price to Earnings (P/E)―
Beta (1Y)69.42
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees157
SectorHealthcare
Sector Strength45
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,597,336
10 Day Avg. Volume87,374
30 Day Avg. Volume69,307
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap444.41K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BIOLASE Business Overview & Revenue Model
Company Description
BIOLASE, Inc. is a medical device company, which engages in the development, manufacture, market and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The...
How the Company Makes Money
BIOLASE generates revenue primarily through the sale of its dental laser systems and related accessories. The company offers a variety of laser products tailored to different dental needs, which are sold directly to dental professionals and throug...
BIOLASE Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | ― | ― | ― | ― | ― |
| Gross Profit | 16.72M | 15.91M | 16.53M | 6.17M | 14.29M |
| EBITDA | -15.02M | -25.28M | -12.32M | -13.84M | -16.59M |
| Net Income | -20.63M | -28.63M | -15.53M | -16.83M | -17.86M |
Balance Sheet | |||||
| Total Assets | 35.10M | 38.19M | 55.25M | 41.02M | 31.85M |
| Cash, Cash Equivalents and Short-Term Investments | ― | ― | ― | ― | ― |
| Total Debt | 14.82M | 15.05M | 15.05M | 17.96M | 13.47M |
| Total Liabilities | 33.15M | 33.30M | 30.08M | 31.00M | 27.50M |
| Stockholders Equity | ― | ― | ― | ― | ― |
Cash Flow | |||||
| Free Cash Flow | -15.23M | -30.49M | -17.42M | -12.89M | -12.95M |
| Operating Cash Flow | -14.10M | -26.76M | -16.71M | -12.79M | -12.75M |
| Investing Cash Flow | ― | ― | ― | ― | ― |
| Financing Cash Flow | ― | ― | ― | ― | ― |
BIOLASE Technical Analysis
Negative
0.01
Price Trends
<0.01
Positive
0.02
Negative
0.17
Negative
Market Momentum
>-0.01
Negative
38.89
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOLQ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, above the 50-day MA of <0.01, and below the 200-day MA of 0.17, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 38.89 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOLQ.
BIOLASE Risk Analysis
BIOLASE disclosed 7 risk factors in its most recent earnings report. BIOLASE reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BIOLASE Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $37.00 | >-0.01 | ― | ― | ― | ― | |
45 Neutral | $14.48M | -0.53 | -189.72% | ― | ― | 70.57% | |
44 Neutral | $3.88M | ― | -203.36% | ― | ― | 90.53% | |
42 Neutral | $2.59M | -0.32 | -262.78% | ― | ― | 79.45% | |
42 Neutral | $1.92M | -0.18 | -145.52% | ― | ― | 97.70% | |
41 Neutral | $595.20K | -0.05 | -2268.26% | ― | -12.39% | 44.61% |
* Healthcare Sector Average
BIOLQ
BIOLASE
0.01
0.00
0.00%
VERO
Venus Concept
0.32
-3.33
-91.23%
ENVB
Enveric Biosciences
1.86
-17.34
-90.31%
INAB
IN8bio
1.47
-4.77
-76.45%
DRMA
Dermata Therapeutics
1.37
-12.83
-90.35%
BJDX
Bluejay Diagnostics
1.98
-13.38
-87.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―